To uncover the role of TLR signaling in brain tumor regression and immunological memory, we developed a syngeneic, intracranial mouse glioma model; treatment consisted of intratumoral delivery of Ads expressing Flt3L and TK (Ad-TK + Ad-Flt3L), followed by systemic delivery of GCV. This evidence concerns the gene TKT and glioma.